STEM, INC.STEMEarnings & Financial Report
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
Revenue
$34.0M
Gross Profit
$9.4M
Operating Profit
$-579.8M
Net Profit
$-582.3M
Gross Margin
27.6%
Operating Margin
-1705.5%
Net Margin
-1712.6%
YoY Growth
-63.4%
EPS
$-71.81
STEM, INC. Q2 FY2024 Financial Summary
STEM, INC. reported revenue of $34.0M (down 63.4% YoY) for Q2 FY2024, with a net profit of $-582.3M (down 3145.0% YoY) (-1712.6% margin). Cost of goods sold was $24.6M, operating expenses totaled $589.2M.
Key Financial Metrics
| Total Revenue | $34.0M |
|---|---|
| Net Profit | $-582.3M |
| Gross Margin | 27.6% |
| Operating Margin | -1705.5% |
| Report Period | Q2 FY2024 |
STEM, INC. Annual Revenue by Year
STEM, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $156.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $156.3M |
| 2024 | $144.6M |
| 2023 | $461.5M |
| 2022 | $363.0M |
STEM, INC. Quarterly Revenue & Net Profit History
STEM, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $47.1M | -15.6% | $-16.0M | -33.9% |
| Q3 FY2025 | $38.2M | +30.5% | $-23.8M | -62.2% |
| Q2 FY2025 | $38.4M | +12.9% | $202.5M | 527.8% |
| Q1 FY2025 | $32.5M | +27.7% | $-25.0M | -76.9% |
| Q4 FY2024 | $55.8M | -66.7% | $-51.1M | -91.6% |
| Q3 FY2024 | $29.3M | -78.1% | $-148.3M | -506.3% |
| Q2 FY2024 | $34.0M | -63.4% | $-582.3M | -1712.6% |
| Q1 FY2024 | $25.5M | -62.2% | $-72.3M | -283.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.5M | $34.0M | $29.3M | $55.8M | $32.5M | $38.4M | $38.2M | $47.1M |
| YoY Growth | -62.2% | -63.4% | -78.1% | -66.7% | 27.7% | 12.9% | 30.5% | -15.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.28B | $691.5M | $537.8M | $437.4M | $405.1M | $379.2M | $362.6M | $308.9M |
| Liabilities | $912.8M | $894.3M | $881.4M | $835.2M | $822.0M | $592.7M | $597.7M | $557.9M |
| Equity | $371.6M | $-203.2M | $-344.1M | $-398.4M | $-417.5M | $-214.1M | $-235.7M | $-249.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-621000 | $-11.9M | $-9.4M | $-14.7M | $8.5M | $-21.3M | $11.4M | $8.2M |